Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028494 | 0.94 | USP30 (0.52) | USP30EPHX2MEN1KMT2AGPR119 | |
| SCHEMBL6036543 | 0.93 | EPHX2 (0.57) | USP30EPHX2MEN1KMT2AGPR119 | |
| SCHEMBL19406085 | 0.91 | ABHD6 (0.52) | USP30EPHX2MEN1KMT2AGPR119 | |
| SCHEMBL9900736 | 0.86 | USP30 (0.58) | USP30MEN1KMT2AGPR119ABHD6 | |
| SCHEMBL9900734 | 0.86 | USP30 (0.58) | USP30MEN1KMT2AGPR119ABHD6 | |
| SCHEMBL9901530 | 0.86 | USP30 (0.58) | USP30MEN1KMT2AGPR119ABHD6 | |
| SCHEMBL23632967 | 0.86 | USP30 (0.57) | USP30EPHX2GPR119PIK3CD | |
| SCHEMBL23632146 | 0.86 | USP30 (0.57) | USP30EPHX2GPR119PIK3CD | |
| SCHEMBL3077366 | 0.86 | USP30 (0.57) | USP30EPHX2GPR119PIK3CD | |
| SCHEMBL12184249 | 0.86 | EPHX2 (0.56) | EPHX2MEN1KMT2AABHD6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| EP-2649061-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2013-10-16 | — | — | EP | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, CNR1 | USP30 4447/4885EPHX2 403/4885MEN1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.